论文部分内容阅读
目的:观察重组人血管内皮抑制素注射液联合伊立替康加卡培他滨治疗晚期结直肠癌的有效性和安全性。方法:手术或化疗后出现复发或转移的晚期结直肠癌患者29例,给予重组人血管内皮抑制素联合伊立替康加卡培他滨化疗,每3周为1个化疗周期。1个化疗周期后评价不良反应,2个化疗周期后评价近期客观疗效,并随访生存情况。结果:28例患者可评价疗效,其中完全缓解(complete response,CR)2例、部分缓解(partial response,PR)11例、疾病稳定(stable disease,SD)7例、疾病进展(progressive disease,PD)8例,临床有效率为46.4%(13/28),临床受益率为71.4%(20/28)。中位无进展生存时间和中位总生存时间分别为6.2和13.7个月。结论:重组人血管内皮抑制素联合化疗治疗晚期结直肠癌的近期疗效较好,不良反应可以耐受。
Objective: To observe the efficacy and safety of recombinant human endostatin injection combined with irinotecan plus capecitabine in the treatment of advanced colorectal cancer. Methods: Twenty-nine patients with recurrent or metastatic advanced colorectal cancer after surgery or chemotherapy were treated with recombinant human endostatin combined with irinotecan plus capecitabine and were given a chemotherapy cycle every 3 weeks. Adverse reactions were evaluated after one cycle of chemotherapy and objective effects were evaluated after two cycles of chemotherapy. Survival was followed up. Results: The curative effect was evaluated in 28 patients, including 2 cases of complete response (CR), 11 cases of partial response (PR), 7 cases of stable disease (SD), 7 cases of progressive disease ) In 8 cases, the clinical effective rate was 46.4% (13/28), the clinical benefit rate was 71.4% (20/28). Median progression-free survival and median overall survival were 6.2 and 13.7 months, respectively. Conclusion: Recombinant human endostatin combined with chemotherapy in the treatment of advanced colorectal cancer has a good short-term effect and adverse reactions can be tolerated.